scholarly journals Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer

2020 ◽  
Vol 14 ◽  
pp. 117955492093181
Author(s):  
Francesca Parisi ◽  
Maria Grazia Razeti ◽  
Eva Blondeaux ◽  
Luca Arecco ◽  
Marta Perachino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Systemic Treatment ◽  
Premenopausal Women ◽  
Specific Patient ◽  
Adjuvant Systemic Treatment ◽  
Current State ◽  
Age Related ◽  
Advanced Stages ◽  
Premenopausal Patients

Breast cancer is the most frequent malignancy diagnosed in premenopausal women. In this age group, breast tumors tend to be diagnosed at more advanced stages and to harbor more aggressive biological features. In addition, specific age-related issues including genetic counseling, fertility preservation, impact on social and couple relationships, working life, and management of long-term side effects should be considered highly relevant when managing early breast cancer in premenopausal women. Therefore, the care of these patients is particularly complex and a multidisciplinary approach is mandatory. The present review summarizes the current state of art in the adjuvant systemic treatment of premenopausal women with early breast cancer focusing on the optimal chemotherapy, endocrine therapy, and targeted therapy approaches in this specific patient population.

scholarly journals Adjuvant systemic treatment of early breast cancer: the NORA study

2006 ◽  
Vol 17 (9) ◽  
pp. 1386-1392 ◽  
Author(s):  
M.E. Cazzaniga ◽  
G. Mustacchi ◽  
P. Pronzato ◽  
A. De Matteis ◽  
F. Di Costanzo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Systemic Treatment ◽  
Adjuvant Systemic Treatment

Is nodal involvement still relevant to assign adjuvant systemic treatment in early breast cancer?

The Breast ◽  
2003 ◽  
Vol 12 ◽  
pp. S25
Author(s):  
M. Gennaro ◽  
A.R. Conti ◽  
C. Ferraris ◽  
P. Lepera ◽  
M. Greco
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Systemic Treatment ◽  
Nodal Involvement ◽  
Adjuvant Systemic Treatment

Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer

2008 ◽  
Vol 26 (2) ◽  
pp. 264-270 ◽  
Author(s):  
Emanuela Rossi ◽  
Alessandro Morabito ◽  
Ermelinda De Maio ◽  
Francesca Di Rella ◽  
Giuseppe Esposito ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Premenopausal Women ◽  
Serum Levels ◽  
Dehydroepiandrosterone Sulfate ◽  
Endocrine Effects ◽  
Exact Test ◽  
Treatment Groups ◽  
Premenopausal Patients

PurposeTo compare the endocrine effects of 6 months of adjuvant treatment with letrozole + triptorelin or tamoxifen + triptorelin in premenopausal patients with early breast cancer within an ongoing phase 3 trial (Hormonal Adjuvant Treatment Bone Effects study).Patients and MethodsProspectively collected hormonal data were available for 81 premenopausal women, of whom 30 were assigned to receive tamoxifen + triptorelin and 51 were assigned letrozole + triptorelin ± zoledronate. Serum 17-β-estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), Δ4-androstenedione, testosterone, dehydroepiandrosterone-sulfate, progesterone, adrenocorticotropic hormone (ACTH), and cortisol were measured at baseline and after 6 months of treatment. For each hormone, 6-month values were compared between treatment groups by the Wilcoxon-Mann-Whitney exact test.ResultsMedian age was 44 years for both groups of patients. Letrozole + triptorelin (± zoledronate) induced a stronger suppression of median E2 serum levels (P = .0008), LH levels (P = .0005), and cortisol serum levels (P < .0001) compared with tamoxifen + triptorelin. Median FSH serum levels were suppressed in both groups, but such suppression was lower among patients receiving letrozole, who showed significantly higher median FSH serum levels (P < .0001). No significant differences were observed for testosterone, progesterone, ACTH, androstenedione, and dehydroepiandrosterone between the two groups of patients.ConclusionLetrozole in combination with triptorelin induces a more intense estrogen suppression than tamoxifen + triptorelin in premenopausal patients with early breast cancer.

Association of response to neoadjuvant chemotherapy (NAC) in premenopausal patients with hormone receptor-positive early breast cancer with chemotherapy-induced ovarian function suppression by NAC.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11017-e11017
Author(s):  
Yutaka Yamamoto ◽  
Risa Yamaguchi ◽  
Yoshitaka Fujiki ◽  
Mutsuko Ibusuki ◽  
Keiichi Murakami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Primary Tumor ◽  
Ovarian Function ◽  
Response Rate ◽  
Premenopausal Women ◽  
Ovarian Function Suppression ◽  
Endocrine Effect ◽  
Premenopausal Patients

e11017 Background: The purpose of this study is to assess the additive endocrine effect by chemotherapy-induced ovarian function suppression (CIOS) for premenopausal women with early breast cancer in neoadjuvant chemotherapy (NAC). Methods: We retrospectively compared the clinical efficacy to NAC between premenopausal and postmenopausal patients with early breast cancer to evaluate the endocrine effect by CIOS. One-hundred twenty two patients received NAC with anthracycline-containing regimen and/or taxane in Kumamoto University Hospital between April 2004 and March 2011. Results: Objective response rate by NAC in premenopausal ER-positive/HER2-negative patients is greater than that in postmenopausal ER-/HER2+ patients (premenopausal 93% vs. postmenopausal 63%, p=0.0121). Reduction rate of primary tumor by NAC on imaging studies in premenopausal ER+/HER2- patients is greater than that in postmenopausal ER-/HER2+ patients (premenopausal 54% vs. postmenopausal 40%, p=0.006). However, no significant difference in response rate between in premenopausal patients with other subtypes and postmenopausal patients with those was found (ER+/HER2+; premenopausal 50% vs. postmenopausal 48%, ER-/HER2+; premenopausal 43% vs. postmenopausal 77%, Triple-negative; premenopausal 86% vs. postmenopausal 65%). All of premenopausal women were suppressed ovarian function within two months after initiation of NAC. Expression levels of progesterone receptor on primary tumor in premenopausal ER+ cancer were significantly decreased after NAC compared with that in postmenopausal ER+ cancer (premenopausal -40.3% vs. postmenopausal +3.6%, p<0.001). Conclusions: These data suggests that CIOS by NAC contributes the additive effects through the endocrine fashion in premenopausal patients with ER+/HER2- breast cancer.

Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review

2014 ◽  
Vol 40 (8) ◽  
pp. 1005-1018 ◽  
Author(s):  
Victoria C. Hamelinck ◽  
Esther Bastiaannet ◽  
Arwen H. Pieterse ◽  
Ilse Jannink ◽  
Cornelis J.H. van de Velde ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Early Breast Cancer ◽  
Systemic Treatment ◽  
Adjuvant Systemic Treatment

scholarly journals Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer

2019 ◽  
pp. 87-91
Author(s):  
L. K. Ovchinnikova ◽  
A. D. Belko
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Early Breast Cancer ◽  
Premenopausal Women ◽  
Gnrh Agonists ◽  
Complex Treatment ◽  
Efficacy And Safety ◽  
Ovarian Suppression ◽  
Premenopausal Patients ◽  
Positive Breast Cancer

Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castration and radiation-based treatment of the ovaries in patients with hormone-positive early breast cancer. Today, several drugs authorised for the treatment of breast cancer are used in clinical practice: goserelin, buserelin and triptorelin. Buserelin-depo is an effective method for achieving ovarian suppression. The results obtained do not differ from similar indicators obtained in using imported LHRH analogues.

Sign in / Sign up

Export Citation Format

Share Document